340B Health says a new survey of its members shows 340B hospitals “are losing significant resources” due to drug companies’ conditions on 340B pricing when covered entities use contract pharmacies.

Hospitals Taking Heavy Losses Due to Drug Company Limits on 340B Pricing, Survey Says

In Pharma Industry, Research/Reports, Trade AssociationJanuary 27, 2022428 Views

Tom Mirga

UPDATE Friday, Jan. 28, 2022—This story was updated to include comments by Pharmaceutical Research and Manufacturers of America (PhRMA.)

340B hospitals “are losing significant resources” due to drug companies’ conditions on 340B pricing when covered entities use contract pharmacies, according to a new survey from hospital group 340B Health.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Hospitals Taking Heavy Losses Due to Drug Company Limits on 340B Pricing, Survey Says

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Hospitals Taking Heavy Losses Due to Drug Company Limits on 340B Pricing, Survey Says

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Site Footer